A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The study is an open label, multicentric, Phase I/II trial aiming to evaluate the safety, the
clinical activity and abscopal anti-tumor effects of a therapeutic strategy associating
Durvalumab in conjunction with SBRT or Durvalumab + Tremelimumab in conjunction with SBRT in
patients with metastatic squamous cell carcinoma of head and neck, lung, or esophagus.